Pacira BioSciences, Inc. (NASDAQ:PCRX) Financial Performance and Competitive Landscape

Core Insights - Pacira BioSciences, Inc. focuses on non-opioid pain management and regenerative health solutions, with its flagship product EXPAREL for postsurgical pain management [1] - The company faces competition from peers such as Supernus Pharmaceuticals, PTC Therapeutics, Ironwood Pharmaceuticals, Ultragenyx Pharmaceutical, and Enanta Pharmaceuticals [1] Financial Performance - Pacira's Return on Invested Capital (ROIC) is 1.74%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 6.19%, indicating inefficiencies in capital utilization [2][6] - Comparatively, Supernus Pharmaceuticals has a negative ROIC of -0.31% against a WACC of 3.02%, also struggling to generate returns above its cost of capital [3] - PTC Therapeutics has a high ROIC of 37.39% and a WACC of 7.70%, resulting in a ROIC to WACC ratio of 4.86, indicating strong capital efficiency [3][5][6] - Ironwood Pharmaceuticals shows effective capital use with a ROIC of 21.34% and a WACC of 5.68%, leading to a ROIC to WACC ratio of 3.76 [4] - Ultragenyx Pharmaceutical and Enanta Pharmaceuticals report negative ROICs of -43.59% and -22.45%, respectively, indicating challenges in generating sufficient returns on their capital [4][6] Competitive Positioning - PTC Therapeutics stands out among its peers with the highest ROIC to WACC ratio, suggesting effective capital utilization and positioning it as a leader in capital efficiency [5]